APA (7th ed.) Citation

Shaefer Jr., C. F. (2016). Lixisenatide: A New Member of the Glucagon-Like Peptide 1 Receptor Agonist Class of Incretin Therapies. Clinical Diabetes, 34(2), 81. https://doi.org/10.2337/diaclin.34.2.81

Chicago Style (17th ed.) Citation

Shaefer Jr., Charles F. "Lixisenatide: A New Member of the Glucagon-Like Peptide 1 Receptor Agonist Class of Incretin Therapies." Clinical Diabetes 34, no. 2 (2016): 81. https://doi.org/10.2337/diaclin.34.2.81.

MLA (9th ed.) Citation

Shaefer Jr., Charles F. "Lixisenatide: A New Member of the Glucagon-Like Peptide 1 Receptor Agonist Class of Incretin Therapies." Clinical Diabetes, vol. 34, no. 2, 2016, p. 81, https://doi.org/10.2337/diaclin.34.2.81.